In order to evaluate the specificity of tumor markers in chronic renal failure, we have determined serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), carbohydrate antigen 50 (CA 50), alfafetoprotein (AFP), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), carbohydrate antigen 15.3 (CA 15.3) and carbohydrate antigen 125 (CA 125) in 30 patients with cronic renal failure and in 36 hemodialyzed patients without clinical evidence of neoplasia. CEA, CA 50, NSE and SCC frequently show increased serum levels, suggesting a renal metabolism, while others remain, generally, within the normal levels.
Purpose: To investigate the diagnostic value of CA 19.9 & CA125 in patients of cancer. Methods: 100 randomly selected patients coming to Medicine & Gynae OPD with symptoms of cancer. Serum was taken and CA19.9 & CA 125 was analyzed by Electrochemiluminescent Immunoassay. Results: It showed serum levels of CA19.9 & CA125 of patient with malignant ovarian, endometriosis & pancreatic tumor significantly higher than the control group. Out of total 50 patients for CA19.9, 45 were females & 5 males. Out of 45 females, 14 females & 3 males have raised value. All 3 males have significantly raised value more than 500 U/ml & All 3 had pancreatic carcinoma. Out of 14 females those had value more than 1000 had features of malignancy whereas rest females of value more than 100 had features of endometriosis. For CA125 total of 50 patients were taken out of which only 10 patients had raised CA125 level. All were females and 60% had value more than cut off that was 35u/ml. Out of the 10 females who had raised CA125, 6 had carcinoma & metastasis & rest 4 had endometriosis.
Carbohydrate Antigen 19-9 (CA19-9) is a tumor marker for the prognosis of colorectal and pancreatic cancers. The high level of this tumor marker in gastric cancer indicates the advanced stage and peritoneal metastasis of the tumor. We reported a case of gastric cancer with an extremely high serum level of CA19-9. We also measured the serum levels of carcinoembryonic antigen and Carbohydrate Antigen 125 in the reported case. Such tumor markers manifest the progression and poor prognosis of cancer. Computed tomography data indicated several lytic and sclerotic foci in the inferior thoracic, lumbar vertebrae, and the right iliac wing, along with invasion to lymph nodes and a right adnexal mass in the reported patient. Bone marrow biopsy results revealed that carcinoma cells were predominantly composed of signet ring cell carcinoma. The patient has expired before receiving any interventions for cancer.
Abstract
BackgroundIntraductal papillary mucinous neoplasm (IPMN) is a disease with malignant potential. IPMNs of the pancreas are mainly managed according to radiographic indications, which lack accuracy in defining grades of IPMNs. Therefore, other indications such as serological biomarkers should be employed to predict the invasiveness of IPMNs.MethodsWe investigated preoperative serum levels of CA19-9, CA125 and CEA of 381 surgical patients with a definite pathological diagnosis of IPMN from July 2010 to December 2019 at Shanghai Cancer Center. We calculated the Youden indices of each point of receiver operating characteristic (ROC) curves to find the most appropriate cut-off values of CA19-9, CA125 and CEA in recognizing malignant IPMNs. Serological biomarker differences were correlated with grades and biological behaviours of IPMNs. Diagnostic indices of these serum biomarkers were calculated.ResultsMalignant group had higher serum levels of CA19-9, CA125 and CEA. According to ROC curves, the most appropriate cut-off value of CA125 were readjusted to 13.5 U/ml while the cut-off values of CA19-9 and CEA remained 37 U/ml and 5.3 ng/l as them mostly be employed. Besides, CA19-9 elevation was significantly associated with vascular invasion and perineural infiltration. We found CA125 may predict invasive IPMN in CA19-9 negative subgroup according to ROC curve. ConclusionsSerological biomarkers are useful and sensitive indications for recognizing invasive IPMNs. CA19-9 has the upmost diagnostic indices among all regularly used serum biomarkers in differentiating malignant and benign IPMNs. CA19-9 should be combined with CA125 to form a more favourable biomarker panel for IPMNs malignancy prediction.
TO ACESS LEVEL OF CA 19.9( CARBOHYDRATE ANTIGEN 19.9) & CA125 (CARBOHYDRATE ANTIGEN 125) IN PATIENTS OF CANCER ( OVARIAN, ENDOMETRIAL & PANCREATIC)